HBM4003 and Triprilimab

DRUG2 trials

Sponsors

Harbour BioMed (Guangzhou) Co. Ltd.

Conditions

Solid Tumors

Phase 1

Study Investigating Safety,Tolerability,Pharmacokinetics and Antitumor Activities of HBM4003 Combine With Toripalimab

Harbour BioMed (Guangzhou) Co. Ltd.Solid Tumors

Start: 2021-02-28End: 2023-11-30Target: 61Updated: 2021-01-29

A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combine With Toripalimab in Patients With Advanced HCC and Other Solid Tumors

Harbour BioMed (Guangzhou) Co. Ltd.Solid Tumors

Start: 2021-12-20End: 2024-05-30Target: 67Updated: 2021-12-08

Related Papers

Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial

Journal for ImmunoTherapy of Cancer2024-10-018 citations

A phase Ib study of porustobart (HBM4003), an anti-CTLA-4 heavy chain only monoclonal antibody, in combination with toripalimab in patients with hepatocellular carcinoma.

Journal of Clinical Oncology2023-06-01

A phase I dose-escalation study of HBM4003, an anti-CTLA-4 heavy chain only monoclonal antibody, in combination with toripalimab in advanced melanoma and other solid tumors.

Journal of Clinical Oncology2022-06-01